Raltegravir use in special populations

European Journal of Medical Research

Volumn 14, Issue SUPPL.3, 2009, Pages 43-46

  Johnson, Margaret ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; INTEGRASE INHIBITOR; RALTEGRAVIR;

FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEOPLASM; ORGAN TRANSPLANTATION; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; TUBERCULOSIS;

FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; NEOPLASMS; ORGAN TRANSPLANTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRROLIDINONES; TUBERCULOSIS;

EID: 77951245691     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-14-S3-43     Document Type: Article

References (18)

1. Rapid and durable antiretroviral therapy effect of in treatment-nave patients with HIV infection: results of a 48 week controlled study. Markovitz M, et al. J Acquir Immune Defic Syndr 2007 46 125 10.1097/QAI.0b013e318157131c 17721395 (Pubitemid 47482607)
2. Subgroup analyses from STARTMARK, a Phase III study of raltegravir based versus efavirenz-based combination therapy in treatment-nave HIV-infected patients. Lennox J, Dejesus E, Lazzarin A, et al. Presented at the 16th Annual Conference on Retroviruses and Opportunistic Infections, Montreal, Canada 2009 abstract # 573
3. Safety and efficacy of the HIV-1 intergrase inhibitor raltegravir (MK-0158) in treatment experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Grinsztejn B, Nguyan BY, Katlama C, et al. Lancet 2007 369 1261 10.1016/S0140-6736(07)60597-2 17434401 (Pubitemid 46553846)
4. 48 week efficacy and safety of MK-0158, a novel HIV-1 intergrase inhibitor in patients with triple class resistant virus. Grinsztejn B, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 2007 (Abstract #H713)
5. Lack of interaction between raltegravir and cyclosporine in an HIV-infected liver transplant recipient. Di Biagio IA, Journal of Antimicrobial Chemotherapy 2009 64 4 874 875 10.1093/jac/dkp269 19643773
6. Safety and efficacy of raltegravir in HIV-infected transplant patients co-treated with immunosuppressive drugs. Tricot L, Am J Transplant 2009 9 8 1946 52 10.1111/j.1600-6143.2009.02684.x 19519819
7. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. Moreno A, AIDS 2008 22 4 547 548 10.1097/QAD.0b013e3282f37478 18301075 (Pubitemid 351317304)
8. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Burgi A, Brodine S, Wenger S, et al. Cancer 2005 104 1505 1511 10.1002/cncr.21334 16104038 (Pubitemid 41356166)
9. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Kirk GD, Merlo C, O'Driscoll P, et al. Clin Infect Dis 2007 45 103 110 10.1086/518606 17554710 (Pubitemid 46984625)
10. Protease inhibitors, potentiate Chemotherapy-induced neutropenia. Bower M, McCall P, Peat N, Ryan N, et al. Blood 2004 104 2943 2946 10.1182/blood-2004-05-1747 15238428 (Pubitemid 39434985)
11. British HIV Association guidelines for the treatment of TB/HIV co-infection 2009-HIV Medicine in press. Pozniak AL, Collins S, Coyne KM, et al.
12. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant women for maternal health and interactions to reduce perinatal HIV transmission in the United States. http://www.AIDSinfo.nih. gov(Accessed July 29th 2008)
13. Antiretroviral Pregnancy Registry International interim report for 1 Jan 1989-31 Jan 2008. Antiretroviral Pregnancy Registry Steering Committee, Willmington, NC: Registry Co-ordinating Centre 2007 Available at: http://www.APRegistry.com
14. Highly active antiretroviral therapy-associated metabolic syndrome: Pathogenesis and cardiovascular risk. Barbaro G, Am J Ther 2006 13 248 10.1097/01.mjt.0000162013.66614.16 16772767 (Pubitemid 44026193)
15. CD4 countguided interruption of antiretroviral treatment. El Sadr WM, Lundgren JD, Neaton JD, et al. N Eng J Med 2006 355 2283 2296 (Pubitemid 44837777)
16. A longitudinal study of changes in circulating markers of endothelial function in HIV patients starting combination ART. 15th Conference on Retroviruses and Opportunistic Infections. Kristofferson US, Kronberg G, Giger AK, Boston MA 2008 Abstract 953
17. Cardiovascular risk factors in HIV patients-association with antiretroviral therapy. Results from DAD Study. Friis-Moller N, Weber R, Reiss P, et al. AIDS 2003 17 1179 1193 10.1097/00002030-200305230-00010 12819520 (Pubitemid 36667761)
18. Switching from stable lopinavir/ritonavir based to raltegravir based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virological efficacy at week 24. Eron J, Andrade J, Zajdenverg R, et al. 16th Conference on Retroviruses and Opportunistic Infections 2009 Montreal, Canada Abstract 70aLB